 |
| << Back | ||||||||||||||||||||||||||||||
| Dyax Corp. to Host First Quarter 2010 Earnings Call and Webcast | ||||||||||||||||||||||||||||||
CAMBRIDGE, Mass., Apr 21, 2010 (BUSINESS WIRE) --Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, April 28, 2010, to discuss its financial results and company progress for the first quarter ended March 31, 2010.
A replay of the conference call will be available through May 28, 2010 and may be accessed by dialing 888-286-8010.International callers should dial 617-801-6888. The replay passcode for all callers is 19111454. The webcast will be archived on the Dyax website for an indefinite period of time. About Dyax Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. Our lead product, DX-88, has been approved under the brand name KALBITOR(R) (ecallantide) in the United States for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older. In addition to its approved commercial use, DX-88 is also being evaluated for its therapeutic potential in other angioedema indications (acquired and ACE inhibitor-induced angioedemas) and, through a collaboration with Fovea Pharmaceuticals (a subsidiary of sanofi aventis), is in a Phase 1 trial for retinal vein occlusion-induced macular edema. DX-88 and other compounds in Dyax's pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts. For online information about Dyax Corp., please visit http://www.dyax.com. SOURCE: Dyax Corp. Dyax Corp. |
|